Transfusion and sickle cell disease: Axes of transfusion safety optimization;Transfusion et drépanocytose : Axes d'optimisation de la sécurité transfusionnelle

Transfusion Clinique et Biologique

Volumn 21, Issue 2, 2014, Pages 77-84

  Noizat Pirenne, F ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

Sickle cell disease; Transfusion

Indexed keywords

ARTICLE; BLOOD BANK; BLOOD DONOR; BLOOD SAFETY; BLOOD TRANSFUSION; ERYTHROCYTE CONCENTRATE; FRANCE; SICKLE CELL ANEMIA; SICKLE CELL TRAIT; ANEMIA, SICKLE CELL; BLOOD GROUP INCOMPATIBILITY; ERYTHROCYTE TRANSFUSION; HUMAN; PATIENT SAFETY; PROCEDURES; STANDARDS; STATISTICS AND NUMERICAL DATA; TRANSFUSION REACTION;

ANEMIA, SICKLE CELL; BLOOD GROUP INCOMPATIBILITY; ERYTHROCYTE TRANSFUSION; FRANCE; HUMANS; PATIENT SAFETY; TRANSFUSION REACTION;

EID: 84901642343     PISSN: 12467820     EISSN: 19538022     Source Type: Journal    
DOI: 10.1016/j.tracli.2014.03.005     Document Type: Article

References (13)

1. Noizat-Pirenne F., Lee K., Pennec P.Y., Simon P., Kazup P., Bachir D., et al. Rare RHCE phenotypes in black individuals of Afro-Caribbean origin: identification and transfusion safety. Blood 2002, 100:4223-4231.
2. Yazdanbakhsh K., Ware R.E., Noizat-Pirenne F. Red cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood 2012, 120:528-537.
3. Zimring J.C., Hendrickson J.E. The role of inflammation in alloimmunization to antigens on transfused red blood cells. Curr Opin Hematol 2008, 15:631-635.
4. Noizat-Pirenne F., Bachir D., Chadebech P., Michel M., Plonquet A., Lecron J.C., et al. Rituximab for prevention of delayed hemolytic transfusion reaction in sickle cell disease. Haematologica 2007, 92:e132-e135.
5. Chadebech P., Habibi A., Nzouakou R., Bachir D., Meunier-Costes N., Bonin P., et al. Delayed hemolytic transfusion reaction in sickle cell disease patients: evidence of an emerging syndrome with suicidal red blood cell death. Transfusion 2009, 49:1785-1792.
6. Adams R.J., McKie V.C., Brambilla D., Carl E., Gallagher D., Nichols F.T., et al. Stroke prevention trial in sickle cell anemia. Control Clin Trials 1998, 19:110-129.
7. Walch E., du Puy-Montbrun M.C., Fournier B., Arditi J.F., Fabrizzi A., Charpentier F., et al. Promotion du don dans la population Afro-Antillaise d'île-de-France et amélioration de la ressource pour les patients drépanocytaires. Transfus Clin Biol 2009, 16:285.
8. Pétapermal M., Elghouzzi M.H., Chamfly V., Bocquet T., Vuittenez M.C., Amiranoff D., et al. Trait drépanocytaire et donneurs d'origine afro-antillaise en île-de-France. Transfus Clin Biol 2009, 16:280.
9. Ould Amar A.K. Red blood cells from donors with sickle cell trait: a safety issue for transfusion?. Transfus Med 2006, 16:248-253.
10. Win N., New H., Lee E., de la J., Fuente Hyperhemolysis syndrome in sickle cell disease: case report (recurrent episode) and literature review. Transfusion 2008, 48:1231-1238.
11. Noizat-Pirenne F., Tournamille C. Relevance of RH variants in transfusion in sickle cell disease. Transfus Clin Biol 2011, 18:527-535.
12. Silvy M., Tournamille C., Babinet J., Pakdaman S., Cohen S., Chiaroni J., et al. Red blood cell immunization in sickle cell disease: evidence of a large responder group and a low rate of anti-Rh linked to partial Rh phenotype. Haematologica 2014, [in press].
13. Peyrard T., Pham B.N., Le Pennec P.Y., Rouger P. The rare blood groups: a public health challenge. Transfus Clin Biol 2008, 15:109-119.